While ACR20 was the primary endpoint, significant improvements were also observed for ACR50 and ACR70. How should we interpret these deeper response rates in terms of disease modification and patient expectations in real-world PsA management?

Sotyktu achieved a PASI 75 response of 51.9% compared to 7.1% with placebo at Week 16. How important is it to see concurrent improvements in both joint and skin domains, and how might that impact treatment decision-making?

Although the prespecified radiographic analysis did not meet significance, a post hoc analysis showed benefit in halting structural damage. How should clinicians interpret this discrepancy, and what are the implications for long-term joint preservation?

Significant improvements were observed in HAQ-DI, SF-36 PCS, and FACIT-Fatigue scores. What does this suggest about Sotyktu’s ability to improve daily function and well-being, particularly in patients with high fatigue burden?

The trial reported improvements in dactylitis and SPARCC enthesitis resolution. How critical is targeting these extra-articular features in comprehensive PsA care, and how does Sotyktu compare to existing oral options in this regard?

In POETYK PsA-2, patients maintained or even improved responses through Week 52. What does this suggest about the long-term disease control potential of deucravacitinib, and how does this compare to existing therapies in chronic PsA management?

With no new safety signals observed and most adverse events being mild, how does Sotyktu’s safety profile position it among oral immunomodulators, especially in light of concerns tied to broader JAK inhibitors?

Given Sotyktu’s unique TYK2 mechanism, where do you see it fitting in current treatment algorithms—particularly for bDMARD-naïve patients or those hesitant about biologics?